

TRENDS-in-MEDICINE

February 27, 2011

by Lynne Peterson

Quick Takes

...Highlights from this week's news affecting drugs and devices in development that are not covered in longer *Trends-in-Medicine* reports...

Trends-in-Medicine

Stephen Snyder, *Publisher* 2731 N.E. Pinecrest Lakes Blvd. Jensen Beach, FL 34957 772-334-7409 Fax 772-334-0856 www.trends-in-medicine.com TrendsInMedicine@aol.com

SHORT TAKES

- Antipsychotics The FDA announced new warning labels for all antipsychotics older agents as well as new atypicals about the risks in pregnancy, including extra-pyramidal symptoms (EPS) and withdrawal symptoms in newborns whose mothers were treated with them during the third trimester. The FDA said it had reports of 69 episodes of neonatal EPS or withdrawal through October 2008, with symptoms including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder.
- BIOGEN IDEC/ELAN'S Tysabri (natalizumab) Cases of progressive multifocal leukoencephalopathy (PML) now total 95 since the multiple sclerosis drug was reintroduced in 2007, and there are now a total of 20 fatalities (including 4 new deaths) this year.
- Biosimilars Speaking to the Generic Pharmaceuticals Association meeting, FDA Commissioner Dr. Margaret Hamburg said her agency plans to release "very soon" regulations to create a pathway for approving follow-on biologics. *The question is what studies the FDA will require, but Dr. Hamburg didn't provide any clarity on that.*
- **CIGNET HEALTHCARE** was fined \$4.3 million by the Department of Health and Human Services (HHS) for HIPAA violations.
- **FOREST LABORATORIES** is acquiring **Clinical Data**, which received FDA approval in January 2011 for its antidepressant Viibryd (vilazodone), a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist for the treatment of major depressive disorder (MDD). Forest plans to launch Viibryd in the U.S. in 2H11.
- **GILEAD SCIENCES** is acquiring privately held **Calistoga Pharmaceuticals**, a biotechnology company that develops cancer and inflammatory disease medications.
- HUMAN GENOME SCIENCES alleged in a lawsuit that Roche/Genentech colluded with Celltech R&D (now part of UCB Pharma) to fraudulently extend the life of the disputed Cabilly patent, which protects technology using recombinant DNA. Human Genome Sciences wants damages and an injunction preventing Genentech from enforcing its patent on the drug.
- LILLY/AVID PHARMACEUTICALS' Amyvid (florbetapir) In January 2011, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 16-0 that this injectable positron emission tomography (PET) brain imaging agent designed to screen for Alzheimer's disease should be approved, but with a validated training program. However, Public Citizen's Health Research Group doesn't agree. Dr. Sidney

Trends-in-Medicine has no financial connections with any pharmaceutical or medical device company. The information and opinions expressed have been compiled or arrived at from sources believed to be reliable and in good faith, but no liability is assumed for information contained in this newsletter. Copyright ©2011. This document may not be reproduced without written permission of the publisher.

Wolfe wrote to Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, that the data are insufficient, not repeatable, inconsistent, and not representative of the population in which it would be used.

- Malaria Researchers at the Georgia Institute of Technology discovered a class of seaweed defense compounds, known as bromophycolides, that may be the source of a new treatment for malaria. The next step would be preclinical animal studies.
- Meningitis The University of Nevada, Reno, and Immuno-Mycologics are collaborating to create a new, low-cost, rapid, point-of-care blood test for the early diagnosis of cryptococcal (fungal) meningitis, a leading cause of AIDS-related deaths in developing countries.
- NICOX's naproxcinod The company said it plans to appeal the FDA's rejection of this anti-inflammatory drug. Hmm, after Roche/Genentech's appeal on Avastin for breast cancer, are appeals going to become more common?
- NOVARTIS/CHIRON's tifacogin A randomized, 2,138patient, multinational study, CAPTIVATE, which was published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine, found that use of this intravenous anti-clotting drug, a recombinant tissue factor pathway inhibitor, does not improve outcomes vs. placebo in patients with severe community-acquired pneumonia (sCAP). Tifacogin had shown some potential benefit in the sCAP subgroup in an earlier study of sepsis patients. This doesn't come as much of a surprise since other trials have failed as well.
- PET changes The U.S. Pharmacopeial Convention is proposing changes in the rules for compounding of radiopharmaceuticals for PET scans. The changes include the addition of microbiological testing of locations where PET drugs are prepared, more quality control measures for PET drug development, and a requirement for proper training of PET drug developers. Public comments on the proposals can be made until March 31, 2011.
- PFIZER/KING PHARMACEUTICALS' Acurox (oxycodone immediate-release) – The FDA granted priority eview designation for this painkiller, and the new PDUFA date is June 17, 2011. Presumably, this is the new nonniacin-containing version.
- ROCHE/GENENTECH's Avastin (bevacizumab) The FDA has scheduled a two-day meeting (June 28-29, 2011) of its Oncologic Drugs Advisory Committee (ODAC) on the company's appeal of the FDA's decision to withdraw the indication for treating metastatic breast cancer that was

granted under accelerated approval but failed to show a benefit in the postmarketing trial.

Don't think this meeting indicates any softening of the FDA position; it's pro forma to hold the panel. However, the politics of the decision over Avastin in breast cancer have escalated since the final decision will be made by Dr. Hamburg.

- SALIX PHARMACEUTICALS' Xifaxin (rifaximin) The company said the FDA advised them that it planned to issue a complete response letter for Xifaxin in non-constipation irritable bowel syndrome (IBS) and IBS-related bloating. The FDA apparently wants additional information on retreatment, including a longer-term clinical trial in patients experiencing recurrent symptoms.
- SAMSUNG GROUP is getting into the pharma business, partnering with Quintiles Transnational to make biologic drugs. Samsung Group plans to expand into producing copies of biologics, such as Roche/Biogen Idec's Rituxan (rituximab), for overseas markets.
- SANTARUS's Rhucin The company's Dutch partner, Pharming, initiated a 50-patient, 12- to 18-month, Phase III trial of this experimental treatment for hereditary angioedema. Santarus could use the results as supportive data if the FDA asks for more data.
- UPSHER-SMITH LABORATORIES First there was a recall of the company's generic warfarin tablets, and now that recall has been expanded to include six other drug product lines that use the same packaging line.
- US WORLDMEDS received a grant of ~\$3 million from the National Institute on Drug Abuse to develop non-narcotic treatments for substance-abuse disorders. The company plans to use the money to test its lofexidine, a non-narcotic treatment to treat the symptoms of heroin and opiate withdrawal.

NEWS IN BRIEF

Bariatric surgery

- what works best for Type 2 diabetes?

Two studies published in *Archives of Surgery* suggested that bypass surgery is better than other bariatric procedures for resolving Type 2 diabetes.

A one-year, pair-matched, cohort analysis of 185 patients by researchers at the University of California San Francisco found that Roux-en-Y gastric bypass surgery was significantly more effective than **Allergan**'s Lap-Band in improving or resolving Type 2 diabetes (76% vs. 50%, p=0.04). The bypass patients lost significantly more weight than the Lap-Band patients (64% of excess weight vs. 36%, p<0.01). Quality of life also was better with bypass surgery.

A randomized trial conducted in Taiwan also found that gastric bypass (but not Roux-en-Y) was more effective than sleeve gastrectomy in resolving Type 2 diabetes (93% vs. 47%, p=0.02). This trial was unusual because it allowed normal-weight people to enter the study.

Heparin

- congressional investigation into contamination

The House Energy and Commerce Committee reopened its investigation into the 2008 Chinese heparin contaminated with oversulfated chondroitin sulfate (OSCS). Chairman Fred Upton (R-MI) and Rep. Michael Burgess (R-TX) – who want to know how the adulteration happened "so that industry and government can take more effective proactive measures to reduce the risk of such adulteration in the future" – asked the FDA to release all documents related to the FDA's investigation of the problem within two weeks.

In their letter to FDA Commissioner Dr. Hamburg, the congressmen said, "There is reason to believe all or some of the individuals responsible for the adulteration are still actively engaged in the Chinese pharmaceutical supply chain and pose a continuing threat to pharmaceutical products imported to the U.S." They said that, despite repeated inquiries over the past three years, federal officials have "largely ignored" their questions about the incident.

Hepatitis C virus (HCV)

- lack of insurance limits outlook for new therapies

A study published in *Hepatology*, the journal of the American Association for the Study of Liver Diseases (AASLD), found that U.S. patients with HCV are twice as likely to be uninsured than people without the disease. The researchers, using the NHANES database from 2005-2008, estimated that only one-third of people with HCV have access to antiviral therapy, either because of lack of insurance or contraindications for therapy. The study found:

- 1.16% of individuals studied were HCV-positive.
- 61% of these had medical insurance.
- 67% of HCV-positive patients were eligible for treatment, but only 54% of those had insurance.
- 36% of HCV-positive patients eligible for antiviral therapy had health insurance.

JOHNSON & JOHNSON – more recalls

- Simponi (golimumab) The company withdrew two lots of injection devices preloaded with Simponi from the U.S. and Europe due to a manufacturing problem discovered during routine quality testing that might prevent full-dose delivery of this therapy for rheumatoid arthritis. J&J said this will cause shortages in Europe. Production of new pens will start by the end of this month; the European shortages may last until May.
- Sudafed (phenylephrine) The company pulled nine lots of extended-release Sudafed in the U.S. because of a "typographical error" in the directions on the label. *Will the recalls ever stop*?

Myeloproliferative neoplasms (MPNs) – potential new treatment discovered

Researchers at the University of Florida, working with colleagues in the U.K. and Hungary, discovered a drug they are calling G6 that targets MPNs, a group of life-threatening and hard-to-diagnose diseases that occur when the bone marrow cranks out too many red blood cells, white cells, or platelets because of a mutant form of JAK2. G6 is a stilbenoid, a family of substances known to slow cell growth and which have antioxidant and tumor-suppressing properties.

In cell cultures and mouse studies, G6 reduced swelling in the spleen, corrected the unhealthily low ratio of white to red blood cells in the bone marrow, and decreased the percentage of immature blood cells circulating through the body.

The potential advantage of this agent over the JAK inhibitors already in development is that G6 appears to change the blood cell composition within the bone marrow, which JAK inhibitors do not do.

The discovery is detailed in an article in the *Journal of Biological Chemistry*. Human clinical trials are expected to start in about a year. So far, the research has been funded in part by the National Institutes of Health (NIH) and the American Heart Association, but the researchers need additional funding to get G6 into the clinic.

PROTALIX BIOTHERAPEUTICS' taliglucerase alfa – rejected by FDA

The company received a complete response letter from the FDA for this synthetic form of glucocerebrosidase to treat Gaucher disease. The Agency said it was dissatisfied with several elements of the company's new drug application (NDA), mostly relating to clinical and chemistry,

manufacturing, and controls (CMC) – testing specifications and assay validation, in particular. The FDA asked for additional data from two trials that were completed after the drug was submitted to the FDA.

Genzyme's Cerezyme (imiglucerase alfa) has been in short supply since 2009 due to manufacturing problems at a Genzyme plant, causing rationing. The FDA temporarily allowed Protalix to distribute taliglucerase alfa during the Cerezyme shortage, but that shortage was recently resolved.

SANOFI-AVENTIS – in trouble with the FDA

Sanofi was warned by the FDA that it has not been reporting potential adverse drug effects or the results of postmarketing studies in a timely manner. And:

- The FDA is not satisfied with the corrective actions the company promised when these deficiencies were brought to its attention three times last year (June, July, and October 2010).
- The FDA said the company doesn't have appropriate procedures for preventing contamination and for staff training at one of its German plants.
- The FDA said Sanofi did not include postmarketing trial information on its diabetes drug Apidra (insulin glulisine), colon cancer drug Eloxatin (oxaliplatin), antibiotic Ketek (telithromycin), and insomnia drug Ambien (zolpidem) in its annual report to the Agency.

Sanofi insisted the issues "will not disrupt its ability to supply products." But that is exactly what could happen unless Sanofi acts quickly and decisively now.

Vertex's VX-770 - remarkable results in cystic fibrosis

The results of the Phase III STRIVE trial showed that this oral drug had very good efficacy in a small subset of cystic fibrosis (CF) patients, those with a mutation in the G551D gene. The trial met the primary endpoint and all the key secondary endpoints. And the results at Week 24 were sustained out to Week 48:

- FEV₁ improved 10.6% vs. placebo (p<0.0001) at Week 24 (the primary endpoint) and 10.5% at Week 48 (p<0.0001).</p>
- VX-770 patients had 55% fewer pulmonary exacerbations and gained an average of 3.1 kilograms at Week 48.
- Sweat chloride was significantly reduced in VX-770 patients vs. placebo.
- VX-770 patients reported fewer respiratory symptoms vs. placebo.

• There was more headache, upper respiratory tract infections, nasal congestion, rash, dizziness, and bacteria in the sputum.

Page 5

March 2011 March 2011 March 2 Discussion of approaches to the development of drugs for orphan and prace disease: including how to utilize biomarkers and pharmacognetics PAP Pharmacoulical Sciences and Clinical Pharmacoul Advices 1 March 2 Session on how to prepare NDA/AMDAs for sadium fluoride F18 as a PTT imaging agent FDA public meeting March 3 Salix Pharmacoulical's Xifaxan (rilaximin) for non-constipution IBS March 4 PDUFA date March 7 Salix Pharmacoulical's (rilaximin) for non-constipution IBS March 8 PDUFA date March 8 Nevarit's Arcapta Noohaler (rilaximin) for non-constipution IBS March 10 Recommendation on scientific (subsc. concerning direct-to consumer (DTO) genetic tests that make medical claims FDA's Molecular and Clinical Genetics Advicory Com genetic tests that make medical claims March 10 Risk of neurodegeneration in pediatric patients from anesthetic drugs discussion of user hatorical-constructed triats as a comparator for anticonvolum in molecular levices (Sectores Sectores Sect	March 2011 Discussion of approaches to the development of drugs for orphan and prace disease, including how to utilize bornardisar, and pharmacognetics. FDA Pharmacoutical Sciences and Clinical Pharmacoulogy Advicory Committee meeting in Dalles, Treass rch 2 Session on how to prepare NDsr/ANDAs for sodium fluoride F18 as a PET FDA public meeting rch 3 Seliz Pharmacouticals' Xifaxan (ridiamin) for non-constipation IBS PDUFA date rch 4 Novartis' Accepta Nobolar (ridicatorial malation), a Ob branchodillator for long-form use in COPD FDA's Puller, and Clinical Genetics Advisory Committee (Recommendation on scientific Issues concerning direct to consumer (OTC) genetic tests that make medical claims FDA's Molecular and Clinical Genetics Advisory Committee (Rocher/Genetics's Lucents (malatinanta) Phase III RISE results in DME The Marala Society meeting rch 10 Rocher/Genetics's Lucents (malatinanta) Phase III RISE results in DME The Marala Society meeting rch 10 GlaxoSonithKilne's Lamatcal XR (amorargine extended relessa) and discussion or use Sciences/CSXS. Sensysta (kilmurnab) for advanced melanas) and thoread devices FDA's Amsthetic and Life Support Drugs Advisory Committee (DN's Perphare) and Cleartal Nerous System Drugs Advisory Committee (DN's Adate rch 10 Human Generom Sciences/CSXS. Sensysta (kilmurnab) for advanced melanas) and thoread devices FDA's Amsthetic and Life Support Drugs Advisory Committee (DN's Adate rch 10 Perleminary deckloin on how to cover E	Date	Tania	Committee/Event		
March 2 Discussion of approaches to the development of drugs for orphn and rare disease, including how to utilize biomarkers and pharmocogenetics March 2 FDD. Pharmocutical Sciences and Clinical Pharmocut Advices Committee methy in balls, less March 5 Session in how to progree ND8A/ADDs for sodium fluoride F18 as a PLT Inaging agent March 5 FDD. Pharmocutical Sciences and PDUFA date March 5 Marck KGar's cladribine for multiple sciences/ bag to multiple sciences/ and the in OPD FDDEFA date March 8 Newrit's Arcepta Nobel/ADDs for sodium fluoride F18 as a PLT Inaginet in OPD FDDEFA date March 9 Recommendation on scientific issues concerning direct-to-corsumer (DTC) genetic tests that make medical claims FDA's Molecular and Clinical Cenetics Advisory Committee ingenetic tests that make medical claims March 10 Resommendation on scientific issues concerning direct-to-corsumer (DTC) genetic tests that make medical claims FDA's Molecular and Clinical Cenetics Advisory Committee instronustant monoherapy in peliptic setures March 10 Resommendical MS (unmotigine scienced-release) anticonsultant monoherapy in peliptic setures FDA's Molecular and Clinical Cenetics Advisory Committee anticonsultant monoherapy in peliptic setures March 10 Human Genome Sciences/GSK's Bentysta Defilmumab) for uppas FDDI/A date March 10 Human Genome Sciences/GSK's Bentysta Defilmumab) for uppasite antinonustant monoherapy in pelippitic setures	area disease Discussion of approaches to the development of drugs for orphan and marging agent. Abio Pointmacignetics citcle Session on how to prepare NUA-XNUXs for sodium fluoride F18 as a PLT imaging agent. FDA public meeting rich 5 (approx.) Marck KGAX's clarifishine for multiple sclerois PDUFA date POUFA date POUFA date POUFA date Point Satix Pharmaceuticals' XIIIxaan (fitaminin) for non-conteption IIIS PDUFA date Point Norvartis' Arcanis Neobaler (industated melaste), a QD benchodillater for FDA's Nutherary-Allergy Drugs Advisory Committee ench 0 Recher/Genetics's Lucas concerning direct-to-consumer (OTC) FDA's Malecular and Clinical Genetics Advisory Committee rich 10 Rick of neurodegeneration in pediaterize patients from anesthetic darges FDA's Malecular and Clinical Cli		Topic March 2011	Committee/Event		
March 2 Sestion on how to prepare NDAc/NDAs for sodium fluoride F18 as a PET FDA public meeting March 5 (approx.) Marck K GaA's cladribine for multiple scherosis POUFA date March 5 (approx.) Marck K GaA's cladribine for multiple scherosis POUFA date March 8 Novertis' Arcapta Noobate (reducatorial maleallo), a OD branchoditator for long-term use in COPD FDA's Pulmonary-Allergy Drugs Advisory Commigents (reducatorial maleatlo), a OD branchoditator for long-term use in COPD March 8-9 Recommended tool on scientific issues concerning direct-to-consumer (DTC) FDA's Molecular and Clinical Genetics Advisory Commigents (reducatoria) March 10 Rocher/Genericch's Lucentific (rabitizination from anesthetic drugs FDA's Anesthetic and Line Sciences/CSK's Genetical VIR (rabitizination monohmergin proping) March 10 Human Genome Sciences/CSK's Gentysta (relimumab) for tipus FDUFA date March 10 Human Genome Sciences/CSK's Gentysta (relimumab) for advinced melanoma FDUFA date March 12 Innovarius enablava for madical davies FDUFA date March 13 Optimer Pharmaceutical's fidaxomicin for the treatment of <i>C. diff</i> FDA Anti-Infection Date Advisory Committee April 2 Novartis's Gleevee (matinib) for GIST PDUFA date April 3 KP AstaTol-Mayers Squ	Substitution on how to prepare NDAr/ANDAs for sodium fluoride F18 as a PET FDA public meeting rch 5 (approx.) Merck KGaA's cladribine for multiple solarosis PDUFA date rch 7 Salix Pharmaceuticals' Klaxan (filiakmin) for non-constipation IBS PDUFA date Novartis' Arcan Fall Noohaler (indexident metalist), a QD broncholillator for FDA's Pulmonary-Allergy Drugs Advisory Committee rek 8-9 Recommendation oscientific issues oncorning direct-to-consumer (OTC) FDA's Molecular and Clinical Genetics Advisory Committee rek 18-9 Recommendation oscientific issues oncorning direct-to-consumer (OTC) FDA's Molecular and Clinical Solary Meeting rek 10 Risk of neurodegeneration in pediatric patients from annashhelic drugs FDA's Molecular and Clinical Solary Meeting rek 10 GlaxosTinthKline's Lametical XR (amortigine oxtended-reless) and discussion of uses of historical-controller trais as a formal for the manshhelic drugs FDA public hearing rek 10 Human Genomes Sciences (SSK'S Selenysta (Lopinumab) for kups PUUFA date rek 20 Bristor-Hyers Squib's Yerry (plinumab) for kups PUUFA date rek 21 Innovative Pathway for medical devices POUFA date rek 21 Depiter Parmaceuticals' fidaxomalin for the treatment of <i>C. attt</i> PDUFA date	March 2	Discussion of approaches to the development of drugs for orphan and			
March S (approx.) Merck KGaA's cladribline for multiple sclerosis PDUFA date March 7 Salix Pharmaceuticals' Xifaxan (rifsdumin) for non-constipution IBS PDUFA date March 8 Novartis' Acaptal Neobattie (indicateron malestel), a QD bronchodilator for genetic tests that make medical claims. FDA's Pulmonary-Allergy Drugs Advisory Committee (modelation on scientific issues concerning direct-to-consumer (DTC) FDA's Melonary-Allergy Drugs Advisory Committee (March 10 Recommendation on scientific issues concerning direct-to-consumer (DTC) FDA's Medical Concerning Advisory Committee (March 10 Recommendation on scientific issues concerning direct-to-consumer (DTC) FDA's Medical Concerning Advisory Committee (March 10 Recommendation on scientific issues concerning direct-to-consumer (DTC) FDA's Medical Concerning Advisory Committee (March 10 Recommendation on scientific issues concerning direct-to-consumer (DTC) FDA's Medical Concerning (March 10 Human Genome Sciences/CSK's Bentysta (kelimumab) for Jupus FDA's Advisory Committee (March 10 FDA's Pulmonary Jupus (March 10) FDA's Advisory Committee (March 16 FPOIFA date March 10 Human Genome Sciences/CSK's Bentysta (kelimumab) for advanced medicancer FDUFA date FDA Advisory Committee (March 16 FDI Advisory Committee (March 16 FDI Advisory Committee (March 17 FDA Advisory Committee (March 16 FDI Advisory Committee (March 16 FDI Advisory Committee (March 16	Interds (approx.) Merck KGaA's cladribine for multiple sclerosis POUFA date rch 7 Salik Pharmaceutical's Xifaxan (rifaximi) for non-constipation IBS POUFA date rch 8 Novarit's Arcpain Neohael (ridication multiple sclerosis) FDA's Putmonary-Allergy Drugs Advisory Committee rch 9 Recommendation on scientific issues concerning direct to consumer (OTC) FDA's Nolecular and Clinical Genetics Advisory Committee rch 10 Roche/Cenentech*s Lucentis (anbizumab) Phase III RISE results in DME The Macula Society meeting rch 10 Rik of neurorosing direct patients from ansulticie (appendixe) FDA's Molecular and Clinical Genetics Advisory Committee rch 10 Rik of neurorosing Advisory System Drugs Advisory Committee FDA's Pelipheral and Central Nervous System Drugs Advisor rch 10 Human Genome Sciences/GSK's Bentysta (belimumab) for laus FDA public hearing rch 15 Innovative Phatrys for medical devises FDA public hearing rch 16 Peliminary decision on how to cover ESAs for kidney disease patients CMS decision rch 16 Politar Phatmaceuticals' fidaxomicin for the treatment of <i>C. dlf</i> FDA Adue rch 16 FDA 510(k) reform FDA folde rdf Astrazeneea's Lactima (anvadviani) for niop	March 2	Session on how to prepare NDAs/ANDAs for sodium fluoride F18 as a PET			
March 7 Salix Pharmaceuticals' Xifaxan (rifaximin) for non-constipation IBS PDUFA date March 8 Novartis' Arcapta Neohaler (inductori maleate), a OD bronchodilator for long-term use in COPD FDA's Pulmonary-Allergy Drugs Advisory Committee (Inductori use in COPD March 8-9 Recommendation on scientific issues concerning direct-to-consumer (DTC) genetic tests that make medical claims FDA's Nethecular and Clinical Genetics: Advisory Committee (Inductori In pediatric patients) in Model FDA's Nethecular and Clinical Genetics: Advisory Committee (Inductori In Pediatric patients) in Model March 10 Risk of neurodegeneration in pediatric patients from anesthelic drugs FDA's Nethecular Mervous System Drugs Committee March 10 Human Genome Sciences/GSK's Bentysta (belimumab) for lupus PDUFA date March 13 Innovative Pathway for medical devices PDUFA date March 14 Preliminary decision on how to cover ESAs for kidney disease patients CMA decision March 15 Innovative Squbic's Vervoy (pilimumab) for advanced melanoma PDUFA date March 16 Preliminary decision on how to cover ESAs for kidney disease patients CMA diction March 26 Dotimer Pharmaceutical' fidaxomic for the treatment of <i>C. dff</i> PDUFA date April 7 AstraZeneca's Zactima (stralpha)droxyprogesteron) to prevert premature brim	Salix Pharmaceuticals' Xifaxan (rifaximir) for non-constipution IBS PDUFA dute Indigitar use in CPD FDA's Pulmonary-Allergy Drugs Advisory Committee (Daystern use) in CPD Indigitar use in CPD FDA's Pulmonary-Allergy Drugs Advisory Committee (Daystern use) in CPD Indigitar use in CPD FDA's Pulmonary-Allergy Drugs Advisory Committee (Daystern use) in CPD India Reche/Genertech's Lucentis (ambizumab) Phase III RISE results in DME The Macula Society meeting (Daystern use) in CPD India Reche/Genertech's Lucentis (ambizumab) Phase III RISE results in DME The Macula Society meeting (Daystern use) in CPD India Reche/Genertech's Lucentis (ambizumab) Phase III RISE results in DME The Macula Society meeting (Daystern use) in CPD India Reche/Genertech's Lucentis (ambizumab) Phase III RISE results in DME The Macula Society meeting (Daystern use) in CPD India Reche/Genertech's Lucentis (ambizumab) Phase III RISE results in DME FDA's Anesthetic and LIFS synthesis Committee intro-outsing medical dovices Intro CHARCE Endertech's Lucentis (Ramotigne extended-release) and discovation in monothere pin peneliptic setures FDA FDA date Intro CHARCE Endertech's Lucentis (Cambizumab) for inparable medulany thread committee FDA Andi-Infective Drugs Advisory Committee Int 2 Novartis's Gleevec (matinib) for GIST FDA Andi-Infective Drugs Advisory Committee Int 2 Astrazencea's Zactima (vandelanib) for inparable medulary thyrrici cancor FDAF date Int 2	March 5 (approx.)		PDUFA date		
Iong-term use in COPD Automation March 8-9 Recommendation on scientific issues concerning direct-to-consumer (DTC) genetic tests that make medical claims FDA's Molecular and Clinical Genetics Advisory Comr genetic tests that make medical claims March 10 Roche/Genentech's Lucentis (ranibizumab) Phase III RISE results in DME The Macuba Society meeting March 10 Risk of neurodegeneration in pediatric patients from anesthelic drugs FDA's Anesthelic and Life Support Drugs Advisory Committee March 10 Human Genome Sciences/CSKY Benlysta (belimumab) for lupus PDUFA date March 10 Human Genome Sciences/CSKY Benlysta (belimumab) for lupus PDUFA date March 10 Human Genome Sciences/CSKY Benlysta (belimumab) for lupus PDUFA date March 10 Human Genome Sciences/CSKY Benlysta (belimumab) for lupus PDUFA date March 10 Human Genome Sciences/CSKY Benlysta (belimumab) for lupus PDUFA date March 10 Human Genome Sciences/CSKY Benlysta (belimumab) for lupus PDUFA date March 12 Novartis's Gleevec (malithi) for GIST PDUFA date April 2 Novartis's Gleevec (malithi) for GIST PDUFA date April 7 AstraZencears's Zactima (nondetanib) for inoperable medullary thyroid cance PDUFA dat	Iong-term use in COPD International Control price Resource of the site of the state metal at claims FDA's Molecular and Clinical Genetics Advisory Committee price Resis that make metal at claims FDA's Molecular and Clinical Genetics Advisory Committee price Resis that make metal at claims FDA's Molecular and Clinical Genetics Advisory Committee price Resis that make metal at claims FDA's Molecular and Clinical Genetics Advisory Committee price Resist that make metal at claims FDA's Molecular and Life Support Drugs Advisory Committee price Resist the make metal at claims FDA's Molecular and Life Support Drugs Advisory Committee price Resist the make metal at claims FDA's Molecular and Life Support Drugs Advisory Committee price Resist the make metal at claims FDA's Molecular and Life Support Drugs Advisory Committee price Resist that make metal at claims FDA's Molecular and Life Support Drugs Advisory Committee price Resist that make metal at claims FDA's Molecular and Life Support Drugs Advisory Committee price Resist that make metal at claims FDA Stote Stote price Resist that make metal at claims FDA Stote Stote price Resist that make metal at claims FDA Stote Stote price Resist that make metal at claims FDA Stote Stote			PDUFA date		
genetic tests that make medical claims Image: Control of the second of the	genetic tests that make medical daims Model arch 10 Roche/Generate/rs Lucentis (ranibizumab) Prase III RISE results in DME The Macula Society meeting arch 10 Risk of neurodegeneration in prediatric patients from anesthelic drugs FDA's Anesthelic and Life Support Drugs Advisory Committee anticonvolution in monibinerating in prediatric patients from anesthelic drugs FDUFA date Committee anticonvolution in monibinerating in prediatric patients from anesthelic drugs FDUFA date FDUFA date anticonvolution in monibinerating in devices April 2011 FDUFA date FDUFA date anticonvolution in monibinerating in devices FDUFA date FDUFA date FDUFA date anticonvolution in monibinerating in for inpertable mediuality throid cancer FDUFA date FDUFA date anticonvolution in anticonvolution in for the treatment of <i>C. dtff</i> FDA stody. Forom FDA stody. prediatric patients duality throid cancer anti 2.8 FDA stody. Forom FDUFA date FDUFA date anti 3.8 KV Pharmaceuticals' telaprevir, a treatment of hepatitis C PDUFA date anti 3.8 KV Pharmaceuticals' telaprevir, a treatment of hepatitis C PDUFA date anti 3.8 KV Pharmaceuticals' telaprevir, a	March 8		FDA's Pulmonary-Allergy Drugs Advisory Committee		
March 10 Risk of neurodegeneration in pediatric patients from anesthetic drugs FDA's Anesthetic and Life Support Drugs Advisory CC March 10 GlaxoSmithKine's Lamictal XR (gmotrigine extended-release) and discussion of use of historial-controlled trials as a comparator for anticonvulsant monotherapy in epilepite selzures FDA's Peripheral and Central Nervous System Drugs Committee March 10 Human Genome Sciences/GSK's Benitysta (belimumab) for lupus PDUFA date March 15 Innovative Pathway for medical devices FDA public hearing March 16 Preliminary decision on how to cover ESAs for kidney disease patients CMS decision March 26 Bristol-Myers Squibb's Yervoy (ipilimumab) for advanced melanoma PDUFA date April 2 Novartis's Gleevec (imatinib) for GIST PDUFA date April 7 AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date April 7.8 FDA 510(k) reform FDA shublic meeting April 10 Open forum to discuss statistical issues related to drug and biologics Joint FDA and Drug Information Agency Forum April 2.3 Vertex Pharmaceutical' telaprovir, a treatment for Apatitis C PDUFA date May 30 Optimer Pharmaceutical's fidaxomicin for the treatment of C. dfff PDUFA date	Intervention Risk of neurodegeneration in pediatric patients from anesthetic drugs FDA's Anesthetic and Life Support Drugs Advisory Commit Intervention GlaxoSmithKline's Lamictal XR (demotrigine extended-release) and discussion of use of historicatic controlled trials as a comparator for anticonvulsant monotherapy in epilepite seizures FDA's Anesthetic and Life Support Drugs Advisory Committee Innovative Pathway for medicial devices FDA public hearing FDA public hearing Innovative Pathway for medicial devices FDA public hearing FDA public hearing Innovative Pathway for medicial devices FDA public hearing FDA public hearing Intro A Bristol-Myers Squibb's Vervoy (pillinumab) for dynamed melanoma PDUFA date Intro A AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date If 1 AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date If 10 Open forum to discuss statistical issues related to drug and biologics Joint FDA and Drug Information Agency Forum If 110 Open forum to discuss statistical issues related to drug and biologics PDUFA date If 23 Vertex Pharmaceuticals' Heaprevir, a treatment for hepatilis C PDUFA date If 10 Open forum to discuss statistical issues related to drug and pologics PDUFA date	March 8-9		FDA's Molecular and Clinical Genetics Advisory Committee		
March 10 GlaxoSmithkline's Lamictal XR (lamotrigine extended-release) and discussion of use of historical-controlled trials as a comparator for anticonvulsant montherapy in epileptic secures FDA's Peripheral and Central Nervous System Drugs Committee March 10 Human Genome Sciences/GSK's Benlysta (belimumab) for lupus PDUFA date March 15 Innovative Pathway for medical devices FDA public hearing March 16 Preliminary decision on how to cover ESAs for kidney disease patients KM decision March 26 Bristol-Myers Squibb's Vervoy (pillimumab) for advanced melanoma PDUFA date April 2 Novartis's Gleevec (mathib) for GIST PDUFA date April 7 AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date April 7.8 FDA S10(k) reform FDA public meeting April 7.8 FDA S10(k) reform FDA public meeting May 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date May 30 Optimer Pharmaceuticals' statistical issues related to drug and biologics Joint FDA and Drug Information Agency Forum May 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date May 30 Optimer Pharmaceuticals' fidaxomicin for the	Class Clas Class Class <thc< td=""><td>March 10</td><td>Roche/Genentech's Lucentis (ranibizumab) Phase III RISE results in DME</td><td>The Macula Society meeting</td></thc<>	March 10	Roche/Genentech's Lucentis (ranibizumab) Phase III RISE results in DME	The Macula Society meeting		
discussion of use of historical-controlled trials as a comparator for anticoonvulsant monothrapy in egliedic seizuresCommitteeMarch 10Human Genome Sciences/GSK's Benlysta (belimumab) for lupusPDUFA dateMarch 15Innovative Pathway for medical devicesFDA public hearingMarch 16Preliminary decision on how to cover ESAs for kidney disease patientsGMS decisionMarch 16Bristol-Myers Squibb's Yervoy (ipilimumab) for advanced melanomaPDUFA dateDut A dateApril 2011April 2011April 2011April 2011April 2016April	aldicausian of use of historical-controlled trials as a comparator for anticonvaluant monotheray in epilepite selectoresCommitteeurch 10Human Genome Sciences/GSK's Benlysta (belinumab) for lupusPDUFA dateurch 15Innovative Pathway for medical devicesEDA public hearingurch 16Preliminary decision on how to cover ESAs for kidney disease patientsCMS decisionvrch 16Bristol-Myers Squibb's Yervoy (pillimumab) for advanced melanomaPDUFA datePOUFA dateOptimer Pharmaceuticals' fidaxomicin for the treatment of C. diffPDUFA dateFDA 510(x) reformFDA 510(x) reformFDA 510(x) reformPOUFA dateOptimer Pharmaceuticals' fidaxomicin for the treatment of C. diffPOUFA datePOUFA dateOptimer Pharmaceuticals' fidaxomicin for the previde and biologicsdevide fidaxomicin for the treatment of C. diffPOUFA datePOUFA date<	March 10	Risk of neurodegeneration in pediatric patients from anesthetic drugs	FDA's Anesthetic and Life Support Drugs Advisory Committe		
March 15 Innovative Pathway for medical devices FDA public hearing March 16 Preliminary decision on how to cover ESAs for kidney disease patients CMS decision March 26 Bristol-Myers Squibb's Yervoy (iplimumab) for advanced melanoma PDUFA date April 2011 April 2011 April 20 Novartis's Gleevec (matinib) for GIST PDUFA date April 5 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> FDA Anti-Infective Drugs Advisory Committee April 7-8 FDA 510(k) reform FDA public meeting April 10 Open forum to discuss statistical issues related to drug and biologics Joint FDA and Drug Information Agency Forum April 13 KV Pharmaceuticals' telaprevir, a treatment for hepatitis C PDUFA date May 23 Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis C PDUFA date May 30 Optimer Pharmaceuticals' Acurox (Immediate-release oxycodone), a painkiller PDUFA date June 13 PTIZEr/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper-resistant oxycodone CR) for pain PDUFA date June 23 PTIZEr/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper-resistant oxycodone CR) for pain PDUFA date June 24-29 Roche/Genentech* S Avastin (bevacirumab), hearing on appeal of FDA's FDA's Coclogic Drugs Advisory Committee (ODAC) <td>Innovative Pathway for medical devices FDA public hearing irrch 16 Preliminary decision on how to cover ESAs for kidney disease patients CMS decision irrch 26 Bristol-Myers Squibb's Yervey (pilimumab) for advanced melanoma PDUFA date irrch 26 Bristol-Myers Squibb's Yervey (pilimumab) for advanced melanoma PDUFA date irl 2 Novartis's Gleevec (imatinib) for GIST PDUFA date irl 3 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> FDA nublic meeting irl 7 AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date irl 10 Open forum to discuss statistical issues related to drug and biologics Joint FDA and Drug Information Agency Forum development and review Vortex Pharmaceuticals' telaprevir, a treatment for hepatitis C PDUFA date y 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date y 30 Optimer Pharmaceuticals' for Kidney disease patients CMS decision ne 17 Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkiller PDUFA date ne 23 Pfizer/King Pharmaceuticals/ Acurox (immediate-release oxycodone), a painkiller PDUFA date y20 AstraZeneca's Brillinta (ticagrelor), an anticoagul</td> <td>March 10</td> <td>discussion of use of historical-controlled trials as a comparator for</td> <td>FDA's Peripheral and Central Nervous System Drugs Advisor Committee</td>	Innovative Pathway for medical devices FDA public hearing irrch 16 Preliminary decision on how to cover ESAs for kidney disease patients CMS decision irrch 26 Bristol-Myers Squibb's Yervey (pilimumab) for advanced melanoma PDUFA date irrch 26 Bristol-Myers Squibb's Yervey (pilimumab) for advanced melanoma PDUFA date irl 2 Novartis's Gleevec (imatinib) for GIST PDUFA date irl 3 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> FDA nublic meeting irl 7 AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date irl 10 Open forum to discuss statistical issues related to drug and biologics Joint FDA and Drug Information Agency Forum development and review Vortex Pharmaceuticals' telaprevir, a treatment for hepatitis C PDUFA date y 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date y 30 Optimer Pharmaceuticals' for Kidney disease patients CMS decision ne 17 Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkiller PDUFA date ne 23 Pfizer/King Pharmaceuticals/ Acurox (immediate-release oxycodone), a painkiller PDUFA date y20 AstraZeneca's Brillinta (ticagrelor), an anticoagul	March 10	discussion of use of historical-controlled trials as a comparator for	FDA's Peripheral and Central Nervous System Drugs Advisor Committee		
March 16 Preliminary decision on how to cover ESAs for kidney disease patients CMS decision March 26 Bristol-Myers Squibb's Yervoy (ipilimumab) for advanced melanoma PDUFA date April 2011 Novartis's Gleevec (imatinib) for GIST PDUFA date April 5 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dttt</i> FDA Anti-Infective Drugs Advisory Committee April 7 AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date April 7.8 FDA 510(k) reform FDA public meeting April 10 Open forum to discuss statistical issues related to drug and biologics Joint FDA and Drug Information Agency Forum April 13 K/ Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date May 23 Vertex Pharmaceuticals' felaprevir, a treatment for hepatilis C PDUFA date May 30 Optimer Pharmaceuticals' felaprevir, a treatment of <i>C. dttt</i> PDUFA date June 17 Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkiller PDUFA date June 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper-resistant oxycodone CR) for pain PDUFA date June 24 Abott's RX Acculink carolid stent	International Control of the second secon	March 10	Human Genome Sciences/GSK's Benlysta (belimumab) for lupus	PDUFA date		
March 26 Bristol-Myers Squibb's Yervoy (plilimumab) for advanced melanoma PDUFA date April 2011 Novartis's Gleevec (matinib) for GIST PDUFA date April 5 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dll</i> ? FDA Anti-Infective Drugs Advisory Committee April 7 AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date April 7-8 FDA 510(k) reform FDA public meeting April 10 Open forum to discuss statistical issues related to drug and biologics development and review Joint FDA and Drug Information Agency Forum April 13 KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date May 23 Vertex Pharmaceuticals' fidaxomicin for the treatment of <i>C. dll</i> ? PDUFA date May 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dll</i> ? PDUFA date June 16 Final decision on coverage of ESAs for kidney disease patients CMS decision June 23 Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a palikiller PDUFA date June 24 Abott's RX Acculink carotid stent FDA's Oncologic Drugs Advisory Committee (ODAC) July 20 AstraZeneca's Brilinta (licagrelor), an anticoa	Bristol-Myers Squibb's Yervoy (pillimumab) for advanced melanoma PDUFA date April 2011 POUFA date rill 5 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dlff</i> FDA Anti-Infective Drugs Advisory Committee rill 7 AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date rill 7.9 FDA 510(k) reform FDA anti-Infective Drugs Advisory Committee rill 10 Open forum to discuss statistical issues related to drug and biologies Joint FDA and Drug Information Agency Forum rill 13 KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date vertex Pharmaceutical/st telaprevir, a treatment for hepatitis C PDUFA date vg 30 Optimer Pharmaceutical's fidaxomicin for the treatment of <i>C. dlff</i> PDUFA date ne 17 Pfizer/King Pharmaceutical/S For kidney disease patients CMS decision ne 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for pain PDUFA date nmmer Report on FDA 510(k) reform PDUFA date 111 Abbott's RX Acculink carotid stent FDA's Oncologic Drugs Advisory Committee (ODAC) decision to Withdraw the indication for metastatic breast cancer<	March 15	Innovative Pathway for medical devices	FDA public hearing		
April 2011 April 2 Novartis's Gleevec (imatinib) for GIST PDUFA date April 5 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dll</i> ? FDA Anti-Infective Drugs Advisory Committee April 7 AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date April 7.8 FDA 510(k) reform FDA 510(k) reform FDA public meeting April 10 Open forum to discuss statistical issues related to drug and biologics development and review Joint FDA and Drug Information Agency Forum April 13 KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date May 23 Vertex Pharmaceuticals' fidaxomicin for the treatment of <i>C. dll</i> ? PDUFA date May 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dll</i> ? PDUFA date June 16 Final decision on coverage of ESAs for kidney disease patients CMS decision June 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for pain PDUFA date Julu 20 AstraZeneca's Evilian (ticagrefor), an anticoagulant PDUFA date 2H11 Abott's RX Acculink carotid stent FDA final decision expected Summer	April 2011 PDUFA date PD	March 16	Preliminary decision on how to cover ESAs for kidney disease patients	CMS decision		
April 2Novartis's Gleevec (imatinib) for GISTPDUFA dateApril 5Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> FDA Anti-Infective Drugs Advisory CommitteeApril 7AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancerPDUFA dateApril 7.8FDA 510(K) reformFDA public meetingApril 10Open forum to discuss statistical issues related to drug and biologics development and reviewJoint FDA and Drug Information Agency ForumApril 13KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birthPDUFA dateOther future 2011 meetings/eventsMay 23Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis CPDUFA dateMay 30Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA dateJune 16Final decision on coverage of ESAs for kidney disease patientsCMS decisionJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA dateJuly 20AstraZeneca's Brillinta (ticagrefor), an anticoagulantPDUFA dateJuny 20AstraZeneca's Brillinta (ticagrefor), an anticoagulantPDUFA dateJuny 20Report on FDA 510(k) reformInstitute of MedicineJuny 20Report on FDA 510(k) reformInstitute of MedicineJuny 20AstraZeneca's Brillinta (ticagrefor), an anticoagulantPDUFA dateZH11Abbot's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine <td>Initial Novartis's Gleevee (imatinib) for GIST PDUFA date Initial Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> FDA Anti-Infective Drugs Advisory Committee Initial AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date Initial FDA 510(K) reform FDA public meeting Joint FDA and Drug Information Agency Forum development and review Initial KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date Vertex Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date Variation Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date vg 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date vg 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date en 16 Final decision on coverage of ESAs for kidney disease patients CMS decision en 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for pain PDUFA date en 28-29 Rocher/Genentech's Avastin (bevadizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancer FDA's Oncologic Drugs Advisory Committee (ODAC) y2 0 AstraZeneca's Brilinta (ticagrefor), an anticoagulant PDUFA date</td> <td>March 26</td> <td>Bristol-Myers Squibb's Yervoy (ipilimumab) for advanced melanoma</td> <td>PDUFA date</td>	Initial Novartis's Gleevee (imatinib) for GIST PDUFA date Initial Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> FDA Anti-Infective Drugs Advisory Committee Initial AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date Initial FDA 510(K) reform FDA public meeting Joint FDA and Drug Information Agency Forum development and review Initial KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date Vertex Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date Variation Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date vg 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date vg 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date en 16 Final decision on coverage of ESAs for kidney disease patients CMS decision en 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for pain PDUFA date en 28-29 Rocher/Genentech's Avastin (bevadizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancer FDA's Oncologic Drugs Advisory Committee (ODAC) y2 0 AstraZeneca's Brilinta (ticagrefor), an anticoagulant PDUFA date	March 26	Bristol-Myers Squibb's Yervoy (ipilimumab) for advanced melanoma	PDUFA date		
April 5Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dlff</i> FDA Anti-Infective Drugs Advisory CommitteeApril 7AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancerPDUFA dateApril 7-8FDA 510(k) reformFDA 510(k) reformFDA public meetingApril 10Open forum to discuss statistical issues related to drug and biologics development and reviewJoint FDA and Drug Information Agency ForumApril 13KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birthPDUFA dateOther future 2011 meetings/eventsMay 23Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis C Harmaceuticals' fidaxomicin for the treatment of <i>C. dlff</i> PDUFA dateJune 16Final decision on coverage of ESAs for kidney disease patients painkillerCMS decisionJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA dateJune 24Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerPDUFA dateJuly 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA dateJuny 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA final decision expectedJumerReport on FDA 510(k) reformInstitute of MedicineSummerReport on FDA 510(k) reformCompany announcement or medical conference presJuny 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stent<	ril 5 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dlff</i> FDA Anti-Infective Drugs Advisory Committee ril 7 AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date ril 7-8 FDA 510(k) reform FDA public meeting of Qeen forum to discuss statistical issues related to drug and biologics Joint FDA and Drug Information Agency Forum development and review Joint FDA and Drug Information Agency Forum of V Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date Other future 2011 meetings/events ay 23 Vertex Pharmaceuticals' fidaxomicin for the treatment of <i>C. dlff</i> PDUFA date PDUFA date privant fidaxomicin for the treatment of <i>C. dlff</i> PDUFA date PDUFA date		April 2011			
April 7AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancerPDUFA dateApril 7-8FDA 510(k) reformFDA 510(k) reformFDA public meetingApril 10Open forum to discuss statistical issues related to drug and biologics development and reviewJoint FDA and Drug Information Agency ForumApril 13KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birthPDUFA dateMay 23Vertex Pharmaceutical' telaprevir, a treatment for hepatitis CPDUFA dateMay 30Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA dateJune 16Final decision on coverage of ESAs for kidney disease patientsCMS decisionJune 23Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkillerPDUFA dateJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA dateJuly 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stentFDA final decision expectedJumerGophtotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference pres4011Ophthotech's ABC-1905 primary endpoint results in prese III HARBOR trial one- year data on the 2 mg dose in wet AMDPDUFA dateOctober 20Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date	Hi AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer PDUFA date Hi 7-8 FDA 510(k) reform FDA public meeting Hi 0 Open forum to discuss statistical issues related to drug and biologics development and review Joint FDA and Drug Information Agency Forum Hi 10 Open forum to discuss statistical issues related to drug and biologics development and review Joint FDA and Drug Information Agency Forum Hi 13 KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis C PDUFA date PDUFA date ay 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dffT</i> PDUFA date PDUFA date ne 16 Final decision on coverage of ESAs for kidney disease patients CMS decision PDUFA date ne 23 Pfizer/King Pharmaceuticals/ Pain Therapeutics' Remoxy (tamperresistant oxycodone CR) for pain PDUFA date PDUFA date ne 28-29 Roche/Genetech's Avastin (bevacizumab), hearing on appeal of FDA's decision expected FDA's Oncologic Drugs Advisory Committee (ODAC) ty 20 AstraZeneca's Brilinta (ticagrelor), an anticoagulant PDUFA date FDA's final decision expected timmer <	April 2	Novartis's Gleevec (imatinib) for GIST	PDUFA date		
April 7-8FDA 510(k) reformFDA public meetingApril 7-8Open forum to discuss statistical issues related to drug and biologics development and reviewJoint FDA and Drug Information Agency ForumApril 10Open forum to discuss statistical issues related to drug and biologics development and reviewJoint FDA and Drug Information Agency ForumApril 13KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birthPDUFA dateOther future 2011 meetings/eventsMay 23Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis CPDUFA dateMay 30Optimer Pharmaceuticals' fidaxomicin for the treatment of C. dfffPDUFA dateJune 16Final decision on coverage of ESAs for kidney disease patientsCMS decisionJune 17Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkillerPDUFA dateJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA dateJune 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)July 20AstraZeneca's Brilinta (ticagrefor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine4Q11Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference pres4Q11Roche/Genentech's Lucentis (ra	FIDA 510(k) reform FDA public meeting ril 10 Open forum to discuss statistical issues related to drug and biologics development and review Joint FDA and Drug Information Agency Forum ril 13 KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date UDEFA date Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis C y 23 Vertex Pharmaceuticals' fidaxomicin for the treatment of <i>C. dllT</i> PDUFA date ay 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dllT</i> PDUFA date ne 16 Final decision on coverage of ESAs for kidney disease patients CMS decision ne 23 Pfizer/King Pharmaceuticals/ Acurox (immediate-release oxycodone), a painkiller PDUFA date ne 28-29 Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancer PDUFA date t11 Abbott's RX Acculink carotid stent FDA final decision expected Institute of Medicine t111 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference presenta t111 Roche/Genemeth's Lucentis (ramibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference presen	April 5	Optimer Pharmaceuticals' fidaxomicin for the treatment of C. diff	FDA Anti-Infective Drugs Advisory Committee		
April 10Open forum to discuss statistical issues related to drug and biologics development and reviewJoint FDA and Drug Information Agency ForumApril 13KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birthPDUFA dateOther future 2011 meetings/eventsMay 23Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis CPDUFA dateMay 30Optimer Pharmaceuticals' fidaxomicin for the treatment of C. diffPDUFA dateJune 16Final decision on coverage of ESAs for kidney disease patientsCMS decisionJune 17Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodene CR) for painPDUFA dateJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodene CR) for painPDUFA dateJune 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)July 20AstraZeneca's Brillinta (ticagrelor), an anticoagulantPDUFA date2111Abbott's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine4011Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference pres4021Zoche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMDCompany announcement or medical conference pres4021Ophthotech's ABC-1905 primary endpoint results cancerPDUFA date </td <td>Init 10Open forum to discuss statistical issues related to drug and biologics development and reviewJoint FDA and Drug Information Agency ForumInit 13KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birthPDUFA dateOther future 2011 meetings/eventsay 23Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis C gata 20PDUFA dateay 23Vertex Pharmaceuticals' fidaxomicin for the treatment of C. diff PDUFA datePDUFA dateay 30Optimer Pharmaceuticals' fidaxomicin for the treatment of C. diffPDUFA datePDUFA datePDUFA datepainkillerPfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPrizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA datePDUFA datePDUFA datePDUFA datePours Advisory Committee (ODAC)decision to withdraw the indication for metastatic breast cancerPDUFA datePDUFA date<td <="" colspan="2" td=""><td>April 7</td><td>AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer</td><td>PDUFA date</td></td></td>	Init 10Open forum to discuss statistical issues related to drug and biologics development and reviewJoint FDA and Drug Information Agency ForumInit 13KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birthPDUFA dateOther future 2011 meetings/eventsay 23Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis C gata 20PDUFA dateay 23Vertex Pharmaceuticals' fidaxomicin for the treatment of C. diff PDUFA datePDUFA dateay 30Optimer Pharmaceuticals' fidaxomicin for the treatment of C. diffPDUFA datePDUFA datePDUFA datepainkillerPfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPrizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA datePDUFA datePDUFA datePDUFA datePours Advisory Committee (ODAC)decision to withdraw the indication for metastatic breast cancerPDUFA datePDUFA date <td <="" colspan="2" td=""><td>April 7</td><td>AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer</td><td>PDUFA date</td></td>	<td>April 7</td> <td>AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer</td> <td>PDUFA date</td>		April 7	AstraZeneca's Zactima (vandetanib) for inoperable medullary thyroid cancer	PDUFA date
development and reviewdevelopmentApril 13KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birthPDUFA dateMay 23Vertex Pharmaceuticals' telaprevir, a treatment for hepatilits CPDUFA dateMay 30Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA dateJune 16Final decision on coverage of ESAs for kidney disease patientsCMS decisionJune 17pfizer/King Pharmaceuticals' Acurox (Immediate-release oxycodone), a painkillerPDUFA dateJune 23Pfizer/King Pharmaceuticals/ for painPDUFA dateJune 24-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)July 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine4Q11Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference pres4Q11Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA dateOctober 20Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date	development and review Construction wril 13 KV Pharmaceutical/Hologic's Gestiva (17-alpha hydroxyprogesterone) to prevent premature birth PDUFA date ay 23 Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis C PDUFA date ay 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date ay 30 Optimer Pharmaceuticals' Acurox (immediate-release oxycodone), a painkiller PDUFA date ne 16 Final decision on coverage of ESAs for kidney disease patients CMS decision ne 17 Pfizer/King Pharmaceuticals/Acurox (immediate-release oxycodone), a painkiller PDUFA date ne 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for pain PDUFA date ne 28-29 Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancer FDA's Oncologic Drugs Advisory Committee (ODAC) ly 20 AstraZeneca's Brilinta (ticagrelor), an anticoagulant PDUFA date 111 Abbott's RX Acculink carotid stent FDA final decision expected mmer Report on FDA 510(k) reform Institute of Medicine 111 Ophthotech's Lucentis (ranibizumab) – Phase II trial in dry AMD Company announcement or medical conference presenta	April 7-8	FDA 510(k) reform	FDA public meeting		
prevent premature birthCother future 2011 meetings/eventsMay 23Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis CPDUFA dateMay 30Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA dateJune 16Final decision on coverage of ESAs for kidney disease patientsCMS decisionJune 17Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkillerPDUFA dateJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA dateJune 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerPDUFA dateJuly 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine4011Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference pres4021Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMDPDUFA date	prevent premature birth Other future 2011 meetings/events ay 23 Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis C PDUFA date ay 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dllf</i> PDUFA date ne 16 Final decision on coverage of ESAs for kidney disease patients CMS decision ne 17 Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkiller PDUFA date ne 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for pain PDUFA date ne 28-29 Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancer FDA's Oncologic Drugs Advisory Committee (ODAC) y20 AstraZeneca's Brillina (ticagrelor), an anticoagulant PDUFA date y21 Abbott's RX Acculink carotid stent FDA final decision expected y21 AstraZeneca's Brilina (ticagrelor), an anticoagulant PDUFA date y21 Abbott's RX Acculink carotid stent FDA final decision expected y21 Report on FDA 510(k) reform Institute of Medicine y21 Abbott's RX-C-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference presenta y21 Johnson & Johnson's	April 10		Joint FDA and Drug Information Agency Forum		
May 23Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis CPDUFA dateMay 30Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. dfff</i> PDUFA dateJune 16Final decision on coverage of ESAs for kidney disease patientsCMS decisionJune 17Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkillerPDUFA dateJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA dateJune 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)July 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine4Q11Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference pres4Q11Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMDPDUFA dateOctober 20Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date	ay 23 Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis C PDUFA date ay 30 Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA date ne 16 Final decision on coverage of ESAs for kidney disease patients CMS decision ne 17 Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkiller PDUFA date ne 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for pain PDUFA date ne 28-29 Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancer FDA's Oncologic Drugs Advisory Committee (ODAC) ty 20 AstraZeneca's Brilinta (ticagrelor), an anticoagulant PDUFA date mmer Report on FDA 510(k) reform Institute of Medicine 011 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference presenta 021 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date 021 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date	April 13		PDUFA date		
May 30Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA dateJune 16Final decision on coverage of ESAs for kidney disease patientsCMS decisionJune 17Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkillerPDUFA dateJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA dateJune 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)July 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine4Q11Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference press4Q11Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMDPDUFA dateOctober 20Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date	ay 30Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i> PDUFA datene 16Final decision on coverage of ESAs for kidney disease patientsCMS decisionne 17Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkillerPDUFA datene 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA datene 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA datene 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)1y 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date111Abbott's RX Acculink carotid stentFDA final decision expected111Opthhotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference presenta121Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMDPDUFA date121Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date121Allergan's brimonidine tartrate intravitreal implant – Phase II trial in dry AMD to completeCompany announcement or medical conference presenta		Other future 2011 meetings/events	1		
June 16Final decision on coverage of ESAs for kidney disease patientsCMS decisionJune 17Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkillerPDUFA dateJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA dateJune 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)July 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine4Q11Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference press4Q11Noche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMDPDUFA dateOctober 20Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date	Final decision on coverage of ESAs for kidney disease patients CMS decision ne 16 Final decision on coverage of ESAs for kidney disease patients CMS decision ne 17 Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkiller PDUFA date ne 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper-resistant oxycodone CR) for pain PDUFA date ne 28 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper-resistant oxycodone CR) for pain PDUFA date ne 28-29 Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancer FDA's Oncologic Drugs Advisory Committee (ODAC) ly 20 AstraZeneca's Brilinta (ticagrelor), an anticoagulant PDUFA date l11 Abbott's RX Acculink carotid stent FDA final decision expected mmer Report on FDA 510(k) reform Institute of Medicine 011 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference presenta 1210 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date 1211 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one-year data on the 2 mg dose in wet AMD Company announcement or medical conference presenta 1210 Johns	May 23	Vertex Pharmaceuticals' telaprevir, a treatment for hepatitis C	PDUFA date		
June 17Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkillerPDUFA dateJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA dateJune 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)July 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine4Q11Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference pres year data on the 2 mg dose in wet AMDOctober 20Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date	Pfizer/King Pharmaceuticals' Acurox (immediate-release oxycodone), a painkiller PDUFA date ne 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper-resistant oxycodone CR) for pain PDUFA date ne 23 Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper-resistant oxycodone CR) for pain PDUFA date ne 28-29 Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancer FDA's Oncologic Drugs Advisory Committee (ODAC) ly 20 AstraZeneca's Brilinta (ticagrelor), an anticoagulant PDUFA date l11 Abbott's RX Acculink carotid stent FDA final decision expected mmer Report on FDA 510(k) reform Institute of Medicine 011 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference presenta 011 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one-year data on the 2 mg dose in wet AMD Company announcement or medical conference presenta ctober 20 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date AMD to complete Company announcement or medical conference presenta	May 30	Optimer Pharmaceuticals' fidaxomicin for the treatment of <i>C. diff</i>	PDUFA date		
painkillerpainkillerJune 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA dateJune 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)July 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine4Q11Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference press4Q11Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMDPDUFA dateOctober 20Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date	painkillerpainkillerne 23Pfizer/King Pharmaceuticals/Pain Therapeutics' Remoxy (tamper- resistant oxycodone CR) for painPDUFA datene 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)ly 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date111Abbott's RX Acculink carotid stentFDA final decision expectedmmerReport on FDA 510(k) reformInstitute of Medicine201Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference presenta201Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMDCompany announcement or medical conference presenta202Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date203Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date204MD to completeCompany announcement or medical conference presenta	June 16	Final decision on coverage of ESAs for kidney disease patients	CMS decision		
resistant oxycodone CR) for painFinal decisionJune 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)July 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA date2H11Abbott's RX Acculink carotid stentFDA final decision expectedSummerReport on FDA 510(k) reformInstitute of Medicine4Q11Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference pression4Q11Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMDCompany announcement or medical conference pressionOctober 20Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA date	resistant oxycodone CR) for painIme 28-29Roche/Genentech's Avastin (bevacizumab), hearing on appeal of FDA's decision to withdraw the indication for metastatic breast cancerFDA's Oncologic Drugs Advisory Committee (ODAC)Ity 20AstraZeneca's Brilinta (ticagrelor), an anticoagulantPDUFA dateIt11Abbott's RX Acculink carotid stentFDA final decision expectedImmerReport on FDA 510(k) reformInstitute of MedicineOphthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMDCompany announcement or medical conference presentaIt11Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMDCompany announcement or medical conference presentaIttober 20Johnson & Johnson's abiraterone for metastatic prostate cancerPDUFA dateIncemperAllergan's brimonidine tartrate intravitreal implant – Phase II trial in dry AMD to completeCompany announcement or medical conference presenta	June 17		PDUFA date		
decision to withdraw the indication for metastatic breast cancer Image: Constraint of the indication for metastatic breast cancer July 20 AstraZeneca's Brilinta (ticagrelor), an anticoagulant PDUFA date 2H11 Abbott's RX Acculink carotid stent FDA final decision expected Summer Report on FDA 510(k) reform Institute of Medicine 4Q11 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference press 4Q11 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference press October 20 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date	decision to withdraw the indication for metastatic breast cancer PDUFA date ly 20 AstraZeneca's Brilinta (ticagrelor), an anticoagulant PDUFA date 111 Abbott's RX Acculink carotid stent FDA final decision expected mmer Report on FDA 510(k) reform Institute of Medicine 201 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference presenta 201 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference presenta 210 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date 220 Allergan's brimonidine tartrate intravitreal implant – Phase II trial in dry AMD to complete Company announcement or medical conference presenta		resistant oxycodone CR) for pain			
2H11 Abbott's RX Acculink carotid stent FDA final decision expected Summer Report on FDA 510(k) reform Institute of Medicine 4Q11 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference press 4Q11 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference press 0ctober 20 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date	Initial Abbott's RX Acculink carotid stent FDA final decision expected Immer Report on FDA 510(k) reform Institute of Medicine 211 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference presenta 211 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference presenta 210 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date 210 Allergan's brimonidine tartrate intravitreal implant – Phase II trial in dry AMD to complete Company announcement or medical conference presenta	June 28-29	decision to withdraw the indication for metastatic breast cancer			
Summer Report on FDA 510(k) reform Institute of Medicine 4Q11 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference press 4Q11 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference press 0ctober 20 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date	mmer Report on FDA 510(k) reform Institute of Medicine 211 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference presenta 211 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference presenta 210 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date 210 Allergan's brimonidine tartrate intravitreal implant – Phase II trial in dry AMD to complete Company announcement or medical conference presenta	-				
4Q11 Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference press 4Q11 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference press October 20 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date	Ophthotech's ARC-1905 primary endpoint results in Phase I trial in dry AMD Company announcement or medical conference presenta 211 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference presenta 210 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date 210 Allergan's brimonidine tartrate intravitreal implant – Phase II trial in dry AMD to complete Company announcement or medical conference presenta	2H11	Abbott's RX Acculink carotid stent	· · ·		
4Q11 Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference press October 20 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date	Roche/Genentech's Lucentis (ranibizumab) – Phase III HARBOR trial one- year data on the 2 mg dose in wet AMD Company announcement or medical conference presenta tober 20 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date ecember Allergan's brimonidine tartrate intravitreal implant – Phase II trial in dry AMD to complete Company announcement or medical conference presenta					
year data on the 2 mg dose in wet AMD Image: Constant of the con	year data on the 2 mg dose in wet AMD PDUFA date stober 20 Johnson & Johnson's abiraterone for metastatic prostate cancer PDUFA date scember Allergan's brimonidine tartrate intravitreal implant – Phase II trial in dry AMD to complete Company announcement or medical conference presenta			Company announcement or medical conference presentation		
	Allergan's brimonidine tartrate intravitreal implant – Phase II trial in dry AMD to complete	4Q11	. ,	Company announcement or medical conference presentation		
	AMD to complete	October 20	Johnson & Johnson's abiraterone for metastatic prostate cancer	PDUFA date		
	2012 meetings /events	December	•	Company announcement or medical conference presentation		